See All Slides - tctmd.com

Slides

Presentation TCT 2012

Case Presentation Conclusion: Procedural and Patient Outcomes(2)

Presenter: Andreas Baumbach

October 25, 2012

Presentation TCT 2012

Managing a Peripheral Coronary Perforation

Presenter: Koen Teeuwen

October 25, 2012

Presentation TCT 2012

Dynamic Obstruction: Mechanisms and Implications for Treatment

Presenter: Carey Kimmelstiel

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

The Radial Learning Curve

Presenter: James Nolan

October 25, 2012

Presentation TCT 2012

A 42-Year-Old Female with True Severe Resistant Hypertension

Presenter: Konstantinos Tsioufis

October 25, 2012

Presentation TCT 2012

2C19 and Warfarin: Clinical Utility or Do New Medications Make It Obsolete?

Presenter: Christopher Granger

October 25, 2012

Presentation TCT 2012

What Is FFR, and How Is It Different from Other Indices?

Presenter: William Fearon

October 25, 2012

Presentation TCT 2012

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Presenter: Suhas Lele

October 25, 2012

Presentation TCT 2012

The European TAVR “Test Track”: After 5 Years, Have TAVR Use Patterns Drifted Out of Control?

Presenter: Nicolo Piazza

October 25, 2012

Advertisement

Slides

Case Presentation Conclusion: Procedural and Patient Outcomes(2)

Managing a Peripheral Coronary Perforation

Dynamic Obstruction: Mechanisms and Implications for Treatment

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

The Radial Learning Curve

A 42-Year-Old Female with True Severe Resistant Hypertension

2C19 and Warfarin: Clinical Utility or Do New Medications Make It Obsolete?

What Is FFR, and How Is It Different from Other Indices?

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

The European TAVR “Test Track”: After 5 Years, Have TAVR Use Patterns Drifted Out of Control?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content